Additional file 1 of Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up

Tian, Xinlun; Yang, Yanli; Chen, Lulu; Sui, Xin; Xu, Wenshuai; Li, Xue; Guo, Xiaobei; Liu, Lingshan; Situ, Yusen; Wang, Jun; Zhao, Yang; Meng, Shuzhen; Song, Wei; Xiao, Yonglong; Xu, Kai-Feng

doi:10.6084/m9.figshare.12607004.v1

13023_2020_1450_MOESM1_ESM.docx (24.83 kB)

Additional file 1 of Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up

journal contribution

posted on 2020-07-03, 04:32 authored by Xinlun Tian, Yanli Yang, Lulu Chen, Xin Sui, Wenshuai Xu, Xue Li, Xiaobei Guo, Lingshan Liu, Yusen Situ, Jun Wang, Yang Zhao, Shuzhen Meng, Wei Song, Yonglong Xiao, Kai-Feng Xu

Additional file 1: Supplemental Table 1. The secondary end point of clinical parameter changes in the 18 months observational periods after 6 months inhaled GM-CSF treatment.

Funding

National Basic Research Program of China (973 Program) National Natural Science Foundation of China the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine

History

Usage metrics

Keywords

Autoimmune pulmonary alveolar proteinosis Granulocyte-macrophage colony stimulating factor Inhalation

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC